NCT05196425CompletedNot Applicable
Expression of PARP-1 in Optic Neuritis of Multiple Sclerosis Patients
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Sohag University
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- measure PARP-1 mRNA
Study Overview
Brief Summary
This study will explore the expression of PARP-1 in optic neuritis of multiple sclerosis patients.
The data will be collected from Sohag University hospital in the period from the start of August 2021 to the end of December 2021.
The study protocol will be approved by the Scientific Research Ethical Committee, Faculty of Medicine, Sohag University.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- Single (Investigator)
Eligibility Criteria
- Ages
- 20 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients with multiple sclerosis with or without optic neuritis Multiple sclerosis will be diagnosed according to the McDonald criteria
Exclusion Criteria
- •• Isolated optic neuritis.
Arms & Interventions
Control group
Other
Intervention: Blood sampling (Genetic)
MS with optic neuritis
Active Comparator
Intervention: Blood sampling (Genetic)
Ms without optic neuritis
Active Comparator
Intervention: Blood sampling (Genetic)
Outcomes
Primary Outcomes
measure PARP-1 mRNA
Time Frame: 2 weeks
measure PARP-1 mRNA
Secondary Outcomes
- Optic nerve, RNFL and GCC layer affection by MS(2 weeks)
Investigators
Elshimaa A.Mateen
Lecturer of ophthalmology
Sohag University
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
REtinal Markers In Neuroinflammatory Diseases ("REMIND")Neuroinflammatory DiseasesMultiple SclerosisNCT06369766University Hospital, Basel, Switzerland500
Withdrawn
Phase 1
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica RelapsesNeuromyelitis OpticaNCT02087813Stanford University
Active, not recruiting
Not Applicable
Impact of Non-Exudative Type 1 MNV on AMD ProgressionNeovascularization, ChoroidalAge-Related Macular DegenerationNCT06125977University of Utah73
Completed
Not Applicable
CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSISChronic Optic Neuropathy in Multiple SclerosisNCT02543788Hospices Civils de Lyon39
Unknown
Not Applicable
Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung AdenocarcinomaLung AdenocarcinomaNCT01249053China Medical University Hospital100